Preview

September 2020

Over the past 100 years, the bacteria samples that make up the National Collection of Type Cultures in the UK have played a vital role in advancing medicine. As the collection celebrates its centenary, we take a look back at the history of this living museum. Looking to modern drug development, we explore the promise of the gut-brain axis as a drug target for gastrointestinal disorders, neurological diseases and mental health conditions.

Also, we get up close with the horseshoe crab to find out why the pharma industry is so reliant on its icy blue blood for safety tests, unpack the complicated topic of puberty blockers to sift the fact from fiction when it comes to these controversial drugs, and take a look at the future of recruitment in pharma, could the industry’s role in tackling Covid-19 help bring more young talent into the sector?

Plus, we examine the findings of Faller Packaging’s recently published sustainability report to learn more about sustainable packaging in pharma, review recent attempts to develop drugs for rare diseases, and debate whether drugs discovered by AI can be patented.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Allie Nawrat, Chris Lo, Abi Millar, Natalie Healey, Chloe Kent, Amy Holder
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | The Route to RecoveryGo to article: In this issueGo to article: MimotopesGo to article: ContentsGo to article: NewsGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: Identifying a viable Covid-19 vaccine candidate and steps needed for its successful implementationGo to article: Impact of Covid-19 on patients with hepatocellular carcinomaGo to article: NSFGo to article: Novavax to receive $1.6B from Operation Warp Speed for the development of Covid-Go to article: FDA winners and losers in Covid-19 therapiesGo to article: Pfeiffer VacuumGo to article: Trials delayed due to Covid-19 begin to resumeGo to article: ILC Dover Go to article: The pharma industry briefingGo to article: From rare diseases to Covid-19: charting the history of Genomics EnglandGo to article: Covid-19: how will pharma cope with a looming recession?Go to article: Pandemic logistics: guaranteeing equitable accessGo to article: Pandemic logistics: Resolving manufacturing and distribution challengesGo to article: KugelmeiersGo to article: Q&A: how to find the right clinical trial participants with Innovative TrialsGo to article: Recce Pharma: a new frontier in the fight against AMRGo to article: Autism pipeline: are better therapies in sight?Go to article: How a new crystallography technique may speed up drug developmentGo to article: Psychedelics: a game-changer in mental health? Go to article: Graph technology: the remedy for broken supply chains is connected dataGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue